The Klotho/FGF23 Axis: A New Mechanism and Therapeutic Prospects for the Cardiorenal Interaction in Chronic Kidney Disease

I. Molecular Basis and Physiological Functions of the Klotho/FGF23 Axis

The Klotho/FGF23 axis has emerged as a critical regulatory system in mineral metabolism homeostasis, garnering increasing attention in chronic kidney disease (CKD) research. Fibroblast growth factor 23 (FGF23), predominantly secreted by osteocytes and osteoblasts, exhibits the characteristic core domain of FGF family proteins along with a unique C-terminal tail structure. Klotho exists in two distinct isoforms: a transmembrane form serving as an obligate co-receptor for FGF23, and a secreted form possessing diverse biological activities independent of FGF23 signaling. Under physiological conditions, FGF23 binds to Klotho-FGFR complexes, activating downstream signaling pathways that regulate renal phosphate reabsorption and 1,25-dihydroxyvitamin D synthesis. This sophisticated regulatory system is indispensable for maintaining systemic mineral homeostasis, with dysregulation at any level potentially precipitating severe metabolic disturbances.

II. Dynamic Alterations of the Klotho/FGF23 Axis During CKD Progression

The natural history of CKD is characterized by profound modifications in the Klotho/FGF23 axis. Early-stage CKD manifests reduced renal Klotho expression concomitant with compensatory elevation of circulating FGF23 levels, representing an adaptive response to declining renal function aimed at preserving mineral balance through enhanced phosphaturia. Progressive renal deterioration exacerbates Klotho deficiency, inducing tissue resistance to FGF23 and driving pathological escalation of FGF23 concentrations. Notably, these dynamic changes not only reflect the degree of renal impairment but also correlate strongly with cardiovascular complication risks in CKD patients. Clinical evidence demonstrates that both diminished Klotho expression and elevated FGF23 levels independently predict all-cause mortality and cardiovascular event rates in this population.

III. Mechanistic Insights into Cardio-Renal Interactions Mediated by the Klotho/FGF23 Axis

Dysregulation of the Klotho/FGF23 axis plays a pivotal role in CKD-associated cardio-renal syndrome pathogenesis. Klotho deficiency directly compromises its vasculoprotective and cardioprotective effects, promoting vascular calcification, myocardial fibrosis, and left ventricular hypertrophy. Conversely, excessive FGF23 exerts direct cardiotoxicity through both Klotho-dependent and independent pathways. The Klotho-dependent mechanism primarily involves FGF23 overactivation-induced disturbances in calcium-phosphate metabolism and secondary hyperparathyroidism, while the Klotho-independent pathway may involve direct FGF23 action on low-affinity receptors in cardiomyocytes, inducing hypertrophic and fibrotic responses. Furthermore, the Klotho/FGF23 axis participates in complex cardio-renal networks through modulation of inflammatory cascades, oxidative stress, and the renin-angiotensin system.

IV. Clinical Utility of the Klotho/FGF23 Axis as Biomarkers

Measurement of Klotho and FGF23 demonstrates considerable clinical value in CKD management. Reductions in soluble Klotho and elevations in FGF23 frequently precede alterations in conventional renal function markers, providing sensitive biomarkers for early CKD detection. These parameters also correlate strongly with disease progression rates and outcomes, facilitating risk stratification and personalized therapeutic decision-making. Particularly noteworthy, the Klotho/FGF23 ratio may offer superior cardiovascular risk prediction compared to individual markers. However, standardization and widespread implementation of Klotho assays remain major challenges requiring technical refinement and multicenter validation studies.

V. Emerging Therapeutic Strategies Targeting the Klotho/FGF23 Axis

Modulation of the Klotho/FGF23 axis represents a promising therapeutic approach for CKD and its cardiovascular complications. Klotho-targeted strategies focus on enhancing endogenous expression through epigenetic modulation, microRNA intervention, or hormonal stimulation, alongside development of stable recombinant Klotho for replacement therapy. For FGF23 modulation, partial inhibition (rather than complete neutralization) appears optimal, with current approaches including FGF23-neutralizing antibodies, soluble Klotho fragments, and FGF23 signaling inhibitors. Particularly intriguing is the potential synergistic effect of combined interventions targeting different axis components, such as concomitant Klotho supplementation and moderate FGF23 suppression, which may restore physiological signaling while avoiding adverse effects of excessive FGF23 inhibition.

VI. Current Challenges and Future Research Directions

Despite significant advances, critical knowledge gaps persist in Klotho/FGF23 axis research. Basic science investigations require deeper elucidation of tissue-specific mechanisms and interactions between Klotho and FGF23. Translational medicine faces challenges in safely applying laboratory discoveries to clinical practice, particularly regarding Klotho protein stability and delivery systems. Clinical research needs large-scale prospective studies to validate biomarker utility and optimize intervention timing and regimens. Additionally, developing personalized Klotho/FGF23 modulation strategies tailored to different CKD stages represents an important future direction.

VII. Conclusions and Perspectives

The Klotho/FGF23 axis serves as a crucial interface between renal and cardiovascular systems, with research advancements enhancing our understanding of cardio-renal interactions in CKD while providing novel diagnostic and therapeutic targets. As knowledge of this system expands, precision medicine strategies based on axis modulation may offer improved therapeutic options for CKD patients. Realizing this potential requires interdisciplinary collaboration to address fundamental and clinical challenges, facilitating translation of research findings into practical applications. Ultimately, investigation of the Klotho/FGF23 axis represents a frontier in nephrology and cardiovascular medicine with substantial academic and clinical implications.